Bosco LabsWhich phase 3 obesity trials of semaglutide or tirzepatide are recruiting in Europe?
condition and intervention are full-text searches (OR combines terms), phase and status use ClinicalTrials.gov's codes and locationCountries Europe matches trials with at least one site in a European country. Each row is one trial with sponsor, enrollment, dates, countries, site_count and a source_url; set detail to full for eligibility, arms and outcomes.
Tool input
{
"condition": "obesity",
"intervention": "semaglutide OR tirzepatide",
"phase": [
"PHASE3"
],
"status": [
"RECRUITING"
],
"locationCountries": [
"Europe"
],
"maxResults": 20
}Ask it from an AI agent (MCP)
Add the Apify MCP server with this tool to your MCP client (Claude, Cursor, VS Code, ...); it signs you in with OAuth or Authorization: Bearer <APIFY_TOKEN>. It works once the Actor is live on the Apify Store.
https://mcp.apify.com?tools=bosco_labs/clinical-trialsThen ask:
Use the bosco_labs/clinical-trials tool to answer: Which phase 3 obesity trials of semaglutide or tirzepatide are recruiting in Europe?Call the Apify API
Runs the Actor and returns the rows in one request, billed to your Apify account ($0.004 per trial). It works once the Actor is live on the Apify Store.
curl https://api.apify.com/v2/acts/bosco_labs~clinical-trials/run-sync-get-dataset-items \
-H "Authorization: Bearer $APIFY_TOKEN" \
-H "Content-Type: application/json" \
-d '{"condition": "obesity", "intervention": "semaglutide OR tirzepatide", "phase": ["PHASE3"], "status": ["RECRUITING"], "locationCountries": ["Europe"], "maxResults": 20}'Example output
Example output from the tool's documentation (not a run of this exact question).
{
"nct_id": "NCT05813925",
"title": "A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight",
"acronym": null,
"status": "COMPLETED",
"phases": ["PHASE3"],
"study_type": "INTERVENTIONAL",
"conditions": ["Obesity or Overweight"],
"interventions": [
{ "type": "DRUG", "name": "Cagrilintide" },
{ "type": "DRUG", "name": "Semaglutide" },
{ "type": "DRUG", "name": "Placebo Semaglutide" }
],
"sponsor": "Novo Nordisk A/S",
"sponsor_class": "INDUSTRY",
"collaborators": [],
"enrollment_count": 331,
"enrollment_type": "ACTUAL",
"start_date": "2023-04-03",
"start_date_type": "ACTUAL",
"primary_completion_date": "2025-01-17",
"primary_completion_date_type": "ACTUAL",
"completion_date": "2025-03-07",
"completion_date_type": "ACTUAL",
"last_update_posted": "2026-01-22",
"countries": ["Japan", "Taiwan"],
"site_count": 28,
"primary_outcomes": [
{
"measure": "Relative Change in Body Weight",
"time_frame": "From baseline (week 0) to end of treatment (week 68)"
}
],
"primary_outcomes_total": 1,
"has_results": false,
"results_first_posted": null,
"brief_summary": "This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week. The study medicine will be injected with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1½ years.",
"eligibility": null,
"arms": null,
"secondary_outcomes": null,
"sites": null,
"source_url": "https://clinicaltrials.gov/study/NCT05813925",
"data_processed_at": "2026-11-05T10:00:06",
"retrieved_at": "2026-11-05T22:38:47+00:00",
"attribution": "Source: ClinicalTrials.gov, a U.S. Government database of the National Library of Medicine (https://clinicaltrials.gov). Data processed by ClinicalTrials.gov on 2026-11-05; data retrieved on 2026-11-05. Modified by Bosco Labs: selected fields only, personal contact details removed, long texts and lists shortened (cut texts end with [truncated]).",
"schema_version": "1"
}